AU · rank #13 · 2026-09-09
FRE
XETRA · EUR · $28.36B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.084 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.01 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 10 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $55.59 | +24.4% |
| Momentum acceleration 3-month minus 12-month momentum. | +20.66% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +25.4% |
| 52w high | $51.53 |
| Market cap (USD) | $28.36B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Fresenius SE is a diversified European healthcare group operating hospital networks (Helios) and infusion/nutrition therapy (Kabi), generating €22.6B in 2025 revenue.
Rationale
With 91.7% revision agreement across 14 analysts, a 24.4% consensus upside, and 60-day EPS revisions turning positive, the analyst upgrade cycle thesis is credibly anchored in Q4 2025's 16% Core EPS growth and management's confirmed 2026 earnings growth guidance.
Material risks
- 1The -6.68% last earnings surprise signals execution risk against elevated expectations — if the REJUVENATE phase delivers below the 5–10% Core EPS growth guide, the revision cycle reverses sharply given 24.3% target dispersion already implies fragile consensus.
- 2Constant-currency guidance masks meaningful EUR/USD and EUR/EM FX translation exposure; any dollar weakening compresses reported EPS and can mechanically trigger analyst target cuts that unwind the revision momentum signal.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.